BD Launches New FDA-Cleared Surgical Wound Wash
BD (Becton, Dickinson and Company) has received FDA 510(k) clearance for Surgiphor™ 1000mL, a sterile, antimicrobial solution for wound irrigation during surgery. The company says it's the first and only product of its kind to get this clearance. The launch aims to provide surgical teams with a consistent solution to improve patient safety and operating room efficiency.
The 510(k) clearance from the U.S. Food and Drug Administration (FDA) is a premarket notification, demonstrating that a new device is "substantially equivalent" to a legally marketed "predicate" device. This is the most common regulatory pathway for Class II (moderate-risk) medical devices, like the Surgiphor™ system, to enter the U.S. market. Surgical site infections (SSIs) are a significant concern, ranking as the second most common hospital-acquired infection in the U.S. They occur in up to 3 out of every 100 patients undergoing surgery, contributing to an estimated $3.5 to $10 billion in annual healthcare costs. The active preservative in Surgiphor™ is povidone-iodine (PVP-I), a broad-spectrum antiseptic. The primary mechanism of action for the irrigation system is the mechanical loosening and removal of debris, including microorganisms, from the wound. Studies have shown that intraoperative irrigation with povidone-iodine can be more effective at preventing SSIs than saline or water alone. Developing a product like Surgiphor™ involves a "tech track" career, such as a Medical Device Product Manager. A person in this role acts as the CEO of the product, conducting market research by talking with doctors and nurses, analyzing competitors, and guiding the product's lifecycle from concept to launch, all while navigating regulatory requirements. On the patient-facing side, a Clinical Research Associate (CRA) plays a key role. A CRA's day involves traveling to hospital sites where clinical trials are active. They are responsible for monitoring the trial, ensuring protocols are followed, verifying data accuracy, and serving as the main line of communication between the study sponsor and the clinical investigators.
